Once-daily prandial lixisenatide versus once-daily rapid-acting insulin in patients with type 2 diabetes mellitus insufficiently controlled with basal insulin: analysis of data from five randomized, controlled trials
The direct cost of replacing degraded ipamorelin is modest (typically $50150 per vial depending on quantity), but the indirect cost of repeating an entire research protocol due to invalid data can exceed $10,00050,000 when accounting for animal subjects, personnel time, and reagent consumption
The Allure of a GLP-1 Patch: Why the Excitement
The largest comparative study to date found no increased risk compared to treatment with insulin, which is considered safe during pregnancy
Giriraj Tosh Purohit is an experienced Product Manager and Security officer with a strong background in healthcare technology and management consulting
Metformin, an AMP-activated protein kinase (AMPK) activator widely used in diabetes, is currently in phase I clinical trials for heart failure with preserved ejection fraction (HFpEF) (Tables 1 and 2)
